White Blood Cell Growth Factors
Key Points
Key Points
Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Diagnosis
...gnosis
...nt Risk Factors for Febrile Neutrop...
...tient Risk Factors for Poor Clinical Outcomes Re...
Treatment for Adult Patients
...tment for Adult Patie...
...y prophylaxis with a CSF starting with th...
...y prophylaxis with a CSF is recommended for pati...
...ld not be routinely used for patients with...
...s should not be routinely used as...
[for breast cancer and lymphoma] ( EB , H ,...
...ial cancer] ( EB , I , B , M )3336...
...sed alone, after chemotherapy, or in combinat...
...e administered after autologous stem...
...administered after allogeneic stem-cell tra...
...CSFs for patients with diffuse aggressive lympho...
...rastim, filgrastim, tbo-filgrastim, and...
...mmendations for the management of pati...
Treatment for Pediatric Patients
...t for Pediatric Patients...
...s in pediatric patients will almost alwa...
...ndications in which dose-intense chemotherapy is k...
...not be used in pediatric patients with nonrel...
Table 3. Dosing and Administration of CSFs
...ing and Administration of CSFsHaving trouble...